Tags

Type your tag names separated by a space and hit enter

A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
J Med Virol. 2022 08; 94(8):3992-3997.JM

Abstract

The SARS-CoV-2 vaccines have been widely used to build an immunologic barrier in the population against the COVID-19 pandemic. However, a newly emerging Omicron variant, including BA.1, BA.1.1, BA.2, and BA.3 sublineages, largely escaped the neutralization of existing neutralizing antibodies (nAbs), even those elicited by three doses of vaccines. Here, we used the Omicron BA.1 RBD as a fourth dose of vaccine to induce potent Omicron-specific nAbs and evaluated the broadly neutralizing activities against SARS-CoV-2 variants. The BA.1-based vaccine was indeed prone to induce a strain-specific antibody response substantially cross-reactive with BA.2 sublineage, and yet triggered broad neutralization against SARS-CoV-2 variants when it was used in the sequential immunization with WT and other variant vaccines. These results demonstrated that the booster of Omicron RBD vaccine could be a rational strategy to enhance the broadly nAb response.

Links

PMC Free PDF

Authors+Show Affiliations

Zhou B
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Song S
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Guo H
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Zhou X
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Fan Q
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Liu W
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Cheng L
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Ge X
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Ju B
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China. Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, Guangdong Province, China.
Zhang Z
Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China. Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, Guangdong Province, China. Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansMiceMice, Inbred BALB CPandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusViral Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35474319

Citation

Zhou, Bing, et al. "A Fourth Dose of Omicron RBD Vaccine Enhances Broad Neutralization Against SARS-CoV-2 Variants Including BA.1 and BA.2 in Vaccinated Mice." Journal of Medical Virology, vol. 94, no. 8, 2022, pp. 3992-3997.
Zhou B, Song S, Guo H, et al. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice. J Med Virol. 2022;94(8):3992-3997.
Zhou, B., Song, S., Guo, H., Zhou, X., Fan, Q., Liu, W., Cheng, L., Ge, X., Ju, B., & Zhang, Z. (2022). A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice. Journal of Medical Virology, 94(8), 3992-3997. https://doi.org/10.1002/jmv.27811
Zhou B, et al. A Fourth Dose of Omicron RBD Vaccine Enhances Broad Neutralization Against SARS-CoV-2 Variants Including BA.1 and BA.2 in Vaccinated Mice. J Med Virol. 2022;94(8):3992-3997. PubMed PMID: 35474319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice. AU - Zhou,Bing, AU - Song,Shuo, AU - Guo,Huimin, AU - Zhou,Xinrong, AU - Fan,Qing, AU - Liu,Weilong, AU - Cheng,Lin, AU - Ge,Xiangyang, AU - Ju,Bin, AU - Zhang,Zheng, Y1 - 2022/05/06/ PY - 2022/04/23/revised PY - 2022/04/05/received PY - 2022/04/25/accepted PY - 2022/4/28/pubmed PY - 2022/6/16/medline PY - 2022/4/27/entrez KW - Omicron variant KW - RBD vaccine KW - SARS-CoV-2 KW - neutralization KW - sequential immunization SP - 3992 EP - 3997 JF - Journal of medical virology JO - J Med Virol VL - 94 IS - 8 N2 - The SARS-CoV-2 vaccines have been widely used to build an immunologic barrier in the population against the COVID-19 pandemic. However, a newly emerging Omicron variant, including BA.1, BA.1.1, BA.2, and BA.3 sublineages, largely escaped the neutralization of existing neutralizing antibodies (nAbs), even those elicited by three doses of vaccines. Here, we used the Omicron BA.1 RBD as a fourth dose of vaccine to induce potent Omicron-specific nAbs and evaluated the broadly neutralizing activities against SARS-CoV-2 variants. The BA.1-based vaccine was indeed prone to induce a strain-specific antibody response substantially cross-reactive with BA.2 sublineage, and yet triggered broad neutralization against SARS-CoV-2 variants when it was used in the sequential immunization with WT and other variant vaccines. These results demonstrated that the booster of Omicron RBD vaccine could be a rational strategy to enhance the broadly nAb response. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/35474319/A_fourth_dose_of_Omicron_RBD_vaccine_enhances_broad_neutralization_against_SARS_CoV_2_variants_including_BA_1_and_BA_2_in_vaccinated_mice_ DB - PRIME DP - Unbound Medicine ER -